GSK PLC 2006 SR
The report outlines GlaxoSmithKline's performance and approach to social, ethical, and environmental issues for the 2006 calendar year. Key highlights include the donation of 155 million albendazole treatments to eliminate lymphatic filariasis and the provision of antiretrovirals at not-for-profit prices to developing nations. The company reported a 1.4% reduction in total energy consumption despite increased sales and achieved a 16% reduction in volatile organic compound emissions. GSK also emphasized its commitment to the '3Rs' in animal research and maintained transparency through its online Clinical Trial Register, which contained 2,760 summaries by year-end.
Company: GSK PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2006
Type: SR
Pages: 81
Back to company
GSK PLC
Corporate Responsibility Report
The report outlines GlaxoSmithKline's performance and approach to social, ethical, and environmental issues for the 2006 calendar year. Key highlights include the donation of 155 million albendazole treatments to eliminate lymphatic filariasis and the provision of antiretrovirals at not-for-profit prices to developing nations. The company reported a 1.4% reduction in total energy consumption despite increased sales and achieved a 16% reduction in volatile organic compound emissions. GSK also emphasized its commitment to the '3Rs' in animal research and maintained transparency through its online Clinical Trial Register, which contained 2,760 summaries by year-end.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2006
Reporting Period
Jan 1, 2006 - Dec 31, 2006
Fiscal Year
2006
Published
Feb 27, 2007
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Women in Management
Workplace Fatalities
Employees